Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability; therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1038 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691646044667904 |
|---|---|
| author | D. I. Abdulganieva A. L. Bakulev E. A. Belousova A. V. Veselov T. V. Korotaeva A. M. Lila E. Yu. Loginova E. V. Sokolovskiy M. M. Khobeish M. V. Shapina O. B. Shchukina |
| author_facet | D. I. Abdulganieva A. L. Bakulev E. A. Belousova A. V. Veselov T. V. Korotaeva A. M. Lila E. Yu. Loginova E. V. Sokolovskiy M. M. Khobeish M. V. Shapina O. B. Shchukina |
| author_sort | D. I. Abdulganieva |
| collection | DOAJ |
| description | Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability; therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important tasks. The paper provides the experts agreed opinion on the definition of the early stage of Ps, PsA, and IBDs, the goals of therapy and main unfavorable prognostic factors for the course of these diseases and gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases. |
| format | Article |
| id | doaj-art-e338338809204dbd8dc7334092900e55 |
| institution | DOAJ |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2020-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-e338338809204dbd8dc7334092900e552025-08-20T03:20:58ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-09-0114371810.14412/1996-7012-2020-3-7-182271Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinionD. I. Abdulganieva0A. L. Bakulev1E. A. Belousova2A. V. Veselov3T. V. Korotaeva4A. M. Lila5E. Yu. Loginova6E. V. Sokolovskiy7M. M. Khobeish8M. V. Shapina9O. B. Shchukina10Kazan State Medical University, Ministry of Health of RussiaV.I. Razumovsky Saratov State Medical University, Ministry of Health of RussiaM.F. Vladimirsky Moscow Regional Research and Clinical InstituteA.N. Ryzhikh National Medical Research Center of Coloproctology, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyDepartment of Dermatovenereology with Clinic, Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaDepartment of Dermatovenereology with Clinic, Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaA.N. Ryzhikh National Medical Research Center of Coloproctology, Ministry of Health of RussiaCity Center for Diagnosis and Treatment of Inflammatory Bowel Diseases, City Clinical Hospital Thirty-OnePsoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability; therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important tasks. The paper provides the experts agreed opinion on the definition of the early stage of Ps, PsA, and IBDs, the goals of therapy and main unfavorable prognostic factors for the course of these diseases and gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases.https://mrj.ima-press.net/mrj/article/view/1038early prescription of biological agentspsoriasispsoriatic arthritiscrohn’s diseaseulcerative colitis |
| spellingShingle | D. I. Abdulganieva A. L. Bakulev E. A. Belousova A. V. Veselov T. V. Korotaeva A. M. Lila E. Yu. Loginova E. V. Sokolovskiy M. M. Khobeish M. V. Shapina O. B. Shchukina Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion Современная ревматология early prescription of biological agents psoriasis psoriatic arthritis crohn’s disease ulcerative colitis |
| title | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion |
| title_full | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion |
| title_fullStr | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion |
| title_full_unstemmed | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion |
| title_short | Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert’s opinion |
| title_sort | early prescription of biological agents for immune mediated inflammatory diseases opportunities and prospects an expert s opinion |
| topic | early prescription of biological agents psoriasis psoriatic arthritis crohn’s disease ulcerative colitis |
| url | https://mrj.ima-press.net/mrj/article/view/1038 |
| work_keys_str_mv | AT diabdulganieva earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT albakulev earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT eabelousova earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT avveselov earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT tvkorotaeva earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT amlila earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT eyuloginova earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT evsokolovskiy earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT mmkhobeish earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT mvshapina earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion AT obshchukina earlyprescriptionofbiologicalagentsforimmunemediatedinflammatorydiseasesopportunitiesandprospectsanexpertsopinion |